ERBB2 and breast cancer: Atezolizumab, an anti-PD-L1 antibody, is being tested in combination with T-DM1 (NCT04740918) in patients with trastuzumab-resistant PD-L1-positive HER2-positive advanced breast cancer; the results of this trial are awaited.